Urinary Calculi Clinical Trial
Official title:
Urinary Proteomic Profiling Using ProteinChip SELDI-TOF-MS: A Potential Means of Identifying Protein Biomarkers of Urinary Stone Formers
Verified date | September 2009 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Observational |
Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 2008 |
Est. primary completion date | November 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Controls: - Ages 18 to 65 years of age - No history of stone disease and no radiographical evidence of stone (as demonstrated by negative ultrasound) - No family history of stones - Healthy and no autoimmune or systemic disease that may affect renal function (see exclusion criteria) Stone patients - Ages 18 to 65 years of age - Solitary stone of any size, in any location along the urinary tract (except lower renal calyceal stones and bladder stones) - Radiology of any modality proving the existence of the stone (ultrasound, computed tomography, intravenous pyelogram, kidney-ureter-bladder x-ray) Exclusion Criteria: - ALL: - Pregnant females - Male patients treated for with benign prostate hyperplasia (BPH) (ongoing medical treatment or surgical intervention within 6 months) - Positive urine culture - Any cancer (excluding superficial skin, brain) - Chronic Recurrent urinary infections (prostate, cystitis, vaginosis/vaginitis) - Gross hematuria - Autoimmune disease that may affect renal function (eg Systemic lupus erythematosus) - Renal dysfunction or its common causes: - Diabetes - Uncontrolled hypertension (with concurrent microalbuminuria) (diastolic BP > 90 mmHg) - glomerulonephritis - Renal transplant - Genetic stone disease (e.g. Cystine stones, xanthinuria) - Medullary sponge kidney, or other renal anomalies such as horseshoe kidney - GI disorders: Inflammatory bowel disease, short bowel - Hypercalcemic disorders (hyperparathyroidism, sarcoidosis, Paget's disease) - Renal tubular acidosis - Immunodeficient patients e.g. HIV (indinavir stones) - Unable to provide informed consent - Anyone in the opinion of the investigator who would be inappropriate Controls : - In addition to criteria above..... - persistent thiazide use - Family history of stones (this will exclude any genetic factors since a positive family history increases the risk of urolithiasis) |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Health Care London | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute | The Physicians' Services Incorporated Foundation, University of Western Ontario, Canada |
Canada,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04924790 -
The Effect of the COVID-19 on Patient Preferences and Decision Making for Obstructive Urinary Stone Interventions
|
||
Recruiting |
NCT05701098 -
SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD)
|
N/A | |
Recruiting |
NCT05574517 -
Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter
|
N/A | |
Withdrawn |
NCT00388271 -
Use of Alfuzosin in Stone Treatment With ESWL
|
Phase 3 | |
Recruiting |
NCT02298465 -
ESWL for Distal Ureteric Stone: Supine Versus Prone
|
N/A | |
Active, not recruiting |
NCT01973088 -
Screening and Identification of Human Urate Transporter hURAT1 MicroRNA
|
N/A | |
Recruiting |
NCT01884870 -
Silent Ureteral Stone: Impact on Renal Function and Kidney Anatomy
|
N/A | |
Active, not recruiting |
NCT00575432 -
Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy
|
||
Completed |
NCT05027971 -
Flexiva Pulse Registry
|
||
Terminated |
NCT00199524 -
Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate
|
Phase 4 | |
Recruiting |
NCT05048706 -
SP TLF Versus Ho:YAG Laser
|
N/A | |
Not yet recruiting |
NCT04110574 -
Computed Tomography Evaluation of Urinary Stones Densities Compared to in Vitro Analysis of Its Chemical Composition
|
||
Recruiting |
NCT02594631 -
Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.
|
Phase 4 | |
Completed |
NCT00857090 -
Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones
|
Phase 1/Phase 2 | |
Completed |
NCT04112160 -
Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal
|
Phase 2 | |
Completed |
NCT04594161 -
Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis
|
N/A | |
Not yet recruiting |
NCT04796792 -
Ultrasound to Facilitate Stone Passage
|
N/A | |
Recruiting |
NCT05270421 -
Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi
|
Phase 3 | |
Completed |
NCT02983409 -
Analysis the Relationship Between the Abdomen CT and Outcomes in Acute Urinary Stone Patients
|
N/A | |
Not yet recruiting |
NCT00397397 -
Comparative Treatment Study in Patients With Lower Ureteral Stones
|
Phase 0 |